Discontinuation of antiseizure medication in patients with epilepsy
Approximately two thirds of patients with epilepsy become seizure-free with antiseizure medication (ASM). A central question is whether and when ASM can be discontinued. To present an overview of the current knowledge about risks and benefits of discontinuation of ASM. Review of the current literatu...
Gespeichert in:
| Veröffentlicht in: | Nervenarzt 2024-12, Vol.95 (12), p.1139 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | ger |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 12 |
| container_start_page | 1139 |
| container_title | Nervenarzt |
| container_volume | 95 |
| creator | Ilyas-Feldmann, Maria Graf, Luise Hüsing, Thea Dörrfuß, Jakob Holtkamp, Martin |
| description | Approximately two thirds of patients with epilepsy become seizure-free with antiseizure medication (ASM). A central question is whether and when ASM can be discontinued.
To present an overview of the current knowledge about risks and benefits of discontinuation of ASM.
Review of the current literature, discussion of data on and recommendations for discontinuation of ASM.
The risk of seizure recurrence after discontinuation of ASM is approximately 40-50% and thus twice as high as continuing with ASM. Guidelines recommend considering discontinuation of ASM at earliest after a seizure-free period of 2 years. Predictive variables for seizure recurrence after stopping ASM include longer duration of epilepsy and higher number of seizures until remission, a shorter seizure-free interval until stopping ASM, older age at epilepsy onset, developmental delay or IQ |
| doi_str_mv | 10.1007/s00115-024-01708-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_3082311250</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3082311250</sourcerecordid><originalsourceid>FETCH-LOGICAL-p141t-bd91824b19d653ae90a4cf215ad24592eb8b95eee5e7bb0798106b3e54ab61b33</originalsourceid><addsrcrecordid>eNpNj0tLxEAQhAdR3HX1D3iQHL2Mds8jkzlKfMKCFz2HmaSDI3mZSZD11xvYFTx1NfV1U8XYJcINApjbCICoOQjFAQ1kXB6xNSopOSgwx__0ip3F-AnLkQE4ZStpQUitYc3y-xDLvptCN7sp9F3S14lb1kjhZx4paakK5d4JXTIsiropJt9h-khoCA0NcXfOTmrXRLo4zA17f3x4y5_59vXpJb_b8gEVTtxXFjOhPNoq1dKRBafKWqB2lVDaCvKZt5qINBnvwdgMIfWStHI-RS_lhl3v_w5j_zVTnIp2CU9N4zrq51hIyIREFBoW9OqAzn6pUAxjaN24K_6Ky1-6N1sv</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3082311250</pqid></control><display><type>article</type><title>Discontinuation of antiseizure medication in patients with epilepsy</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Ilyas-Feldmann, Maria ; Graf, Luise ; Hüsing, Thea ; Dörrfuß, Jakob ; Holtkamp, Martin</creator><creatorcontrib>Ilyas-Feldmann, Maria ; Graf, Luise ; Hüsing, Thea ; Dörrfuß, Jakob ; Holtkamp, Martin</creatorcontrib><description>Approximately two thirds of patients with epilepsy become seizure-free with antiseizure medication (ASM). A central question is whether and when ASM can be discontinued.
To present an overview of the current knowledge about risks and benefits of discontinuation of ASM.
Review of the current literature, discussion of data on and recommendations for discontinuation of ASM.
The risk of seizure recurrence after discontinuation of ASM is approximately 40-50% and thus twice as high as continuing with ASM. Guidelines recommend considering discontinuation of ASM at earliest after a seizure-free period of 2 years. Predictive variables for seizure recurrence after stopping ASM include longer duration of epilepsy and higher number of seizures until remission, a shorter seizure-free interval until stopping ASM, older age at epilepsy onset, developmental delay or IQ < 70, febrile seizures in childhood, absence of a self-limiting epilepsy syndrome, and evidence of epileptiform activity in the electroencephalograph (EEG). The individual risk of seizure recurrence after stopping ASM can be estimated using an online prediction tool.
Discontinuation of ASM should be discussed with patients at the earliest after 2 years of seizure freedom in a shared decision-making process weighing up the risks and benefits. The risk of a seizure recurrence depends on a number of clinical variables. Psychosocial aspects, such as impact on driving and occupational issues must be taken into consideration as well as individual fears and concerns of patients about seizure recurrence or the long-term use of ASM.</description><identifier>ISSN: 1433-0407</identifier><identifier>EISSN: 1433-0407</identifier><identifier>DOI: 10.1007/s00115-024-01708-3</identifier><identifier>PMID: 39023550</identifier><language>ger</language><publisher>Germany</publisher><subject>Anticonvulsants - adverse effects ; Anticonvulsants - therapeutic use ; Epilepsy - drug therapy ; Humans ; Recurrence ; Risk Assessment ; Risk Factors ; Withholding Treatment</subject><ispartof>Nervenarzt, 2024-12, Vol.95 (12), p.1139</ispartof><rights>2024. The Author(s).</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39023550$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ilyas-Feldmann, Maria</creatorcontrib><creatorcontrib>Graf, Luise</creatorcontrib><creatorcontrib>Hüsing, Thea</creatorcontrib><creatorcontrib>Dörrfuß, Jakob</creatorcontrib><creatorcontrib>Holtkamp, Martin</creatorcontrib><title>Discontinuation of antiseizure medication in patients with epilepsy</title><title>Nervenarzt</title><addtitle>Nervenarzt</addtitle><description>Approximately two thirds of patients with epilepsy become seizure-free with antiseizure medication (ASM). A central question is whether and when ASM can be discontinued.
To present an overview of the current knowledge about risks and benefits of discontinuation of ASM.
Review of the current literature, discussion of data on and recommendations for discontinuation of ASM.
The risk of seizure recurrence after discontinuation of ASM is approximately 40-50% and thus twice as high as continuing with ASM. Guidelines recommend considering discontinuation of ASM at earliest after a seizure-free period of 2 years. Predictive variables for seizure recurrence after stopping ASM include longer duration of epilepsy and higher number of seizures until remission, a shorter seizure-free interval until stopping ASM, older age at epilepsy onset, developmental delay or IQ < 70, febrile seizures in childhood, absence of a self-limiting epilepsy syndrome, and evidence of epileptiform activity in the electroencephalograph (EEG). The individual risk of seizure recurrence after stopping ASM can be estimated using an online prediction tool.
Discontinuation of ASM should be discussed with patients at the earliest after 2 years of seizure freedom in a shared decision-making process weighing up the risks and benefits. The risk of a seizure recurrence depends on a number of clinical variables. Psychosocial aspects, such as impact on driving and occupational issues must be taken into consideration as well as individual fears and concerns of patients about seizure recurrence or the long-term use of ASM.</description><subject>Anticonvulsants - adverse effects</subject><subject>Anticonvulsants - therapeutic use</subject><subject>Epilepsy - drug therapy</subject><subject>Humans</subject><subject>Recurrence</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Withholding Treatment</subject><issn>1433-0407</issn><issn>1433-0407</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNj0tLxEAQhAdR3HX1D3iQHL2Mds8jkzlKfMKCFz2HmaSDI3mZSZD11xvYFTx1NfV1U8XYJcINApjbCICoOQjFAQ1kXB6xNSopOSgwx__0ip3F-AnLkQE4ZStpQUitYc3y-xDLvptCN7sp9F3S14lb1kjhZx4paakK5d4JXTIsiropJt9h-khoCA0NcXfOTmrXRLo4zA17f3x4y5_59vXpJb_b8gEVTtxXFjOhPNoq1dKRBafKWqB2lVDaCvKZt5qINBnvwdgMIfWStHI-RS_lhl3v_w5j_zVTnIp2CU9N4zrq51hIyIREFBoW9OqAzn6pUAxjaN24K_6Ky1-6N1sv</recordid><startdate>202412</startdate><enddate>202412</enddate><creator>Ilyas-Feldmann, Maria</creator><creator>Graf, Luise</creator><creator>Hüsing, Thea</creator><creator>Dörrfuß, Jakob</creator><creator>Holtkamp, Martin</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>202412</creationdate><title>Discontinuation of antiseizure medication in patients with epilepsy</title><author>Ilyas-Feldmann, Maria ; Graf, Luise ; Hüsing, Thea ; Dörrfuß, Jakob ; Holtkamp, Martin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p141t-bd91824b19d653ae90a4cf215ad24592eb8b95eee5e7bb0798106b3e54ab61b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>ger</language><creationdate>2024</creationdate><topic>Anticonvulsants - adverse effects</topic><topic>Anticonvulsants - therapeutic use</topic><topic>Epilepsy - drug therapy</topic><topic>Humans</topic><topic>Recurrence</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Withholding Treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ilyas-Feldmann, Maria</creatorcontrib><creatorcontrib>Graf, Luise</creatorcontrib><creatorcontrib>Hüsing, Thea</creatorcontrib><creatorcontrib>Dörrfuß, Jakob</creatorcontrib><creatorcontrib>Holtkamp, Martin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Nervenarzt</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ilyas-Feldmann, Maria</au><au>Graf, Luise</au><au>Hüsing, Thea</au><au>Dörrfuß, Jakob</au><au>Holtkamp, Martin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Discontinuation of antiseizure medication in patients with epilepsy</atitle><jtitle>Nervenarzt</jtitle><addtitle>Nervenarzt</addtitle><date>2024-12</date><risdate>2024</risdate><volume>95</volume><issue>12</issue><spage>1139</spage><pages>1139-</pages><issn>1433-0407</issn><eissn>1433-0407</eissn><abstract>Approximately two thirds of patients with epilepsy become seizure-free with antiseizure medication (ASM). A central question is whether and when ASM can be discontinued.
To present an overview of the current knowledge about risks and benefits of discontinuation of ASM.
Review of the current literature, discussion of data on and recommendations for discontinuation of ASM.
The risk of seizure recurrence after discontinuation of ASM is approximately 40-50% and thus twice as high as continuing with ASM. Guidelines recommend considering discontinuation of ASM at earliest after a seizure-free period of 2 years. Predictive variables for seizure recurrence after stopping ASM include longer duration of epilepsy and higher number of seizures until remission, a shorter seizure-free interval until stopping ASM, older age at epilepsy onset, developmental delay or IQ < 70, febrile seizures in childhood, absence of a self-limiting epilepsy syndrome, and evidence of epileptiform activity in the electroencephalograph (EEG). The individual risk of seizure recurrence after stopping ASM can be estimated using an online prediction tool.
Discontinuation of ASM should be discussed with patients at the earliest after 2 years of seizure freedom in a shared decision-making process weighing up the risks and benefits. The risk of a seizure recurrence depends on a number of clinical variables. Psychosocial aspects, such as impact on driving and occupational issues must be taken into consideration as well as individual fears and concerns of patients about seizure recurrence or the long-term use of ASM.</abstract><cop>Germany</cop><pmid>39023550</pmid><doi>10.1007/s00115-024-01708-3</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1433-0407 |
| ispartof | Nervenarzt, 2024-12, Vol.95 (12), p.1139 |
| issn | 1433-0407 1433-0407 |
| language | ger |
| recordid | cdi_proquest_miscellaneous_3082311250 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Anticonvulsants - adverse effects Anticonvulsants - therapeutic use Epilepsy - drug therapy Humans Recurrence Risk Assessment Risk Factors Withholding Treatment |
| title | Discontinuation of antiseizure medication in patients with epilepsy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T01%3A30%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Discontinuation%20of%20antiseizure%20medication%20in%20patients%20with%20epilepsy&rft.jtitle=Nervenarzt&rft.au=Ilyas-Feldmann,%20Maria&rft.date=2024-12&rft.volume=95&rft.issue=12&rft.spage=1139&rft.pages=1139-&rft.issn=1433-0407&rft.eissn=1433-0407&rft_id=info:doi/10.1007/s00115-024-01708-3&rft_dat=%3Cproquest_pubme%3E3082311250%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3082311250&rft_id=info:pmid/39023550&rfr_iscdi=true |